Publications by authors named "Mahesh Napel"
Article Synopsis
- Upadacitinib shows promise as a treatment for moderate-to-severe inflammatory bowel diseases, potentially improving both short-term and long-term patient outcomes.
- A meta-analysis of studies published from 2010 to 2024 included data from 2,818 patients, revealing a clinical remission rate of 45.8% for Crohn's disease and 25.4% for ulcerative colitis.
- The medication also has a favorable safety profile, with a serious adverse event rate of 6.0%, making it a viable option for patients who do not respond to traditional treatments.
Background: Endoscopic submucosal dissection (ESD) for gastric neoplasms can be challenging due to limited traction and visualization. The efficacy of traction-assisted endoscopic submucosal dissection (TA-ESD) continues to require additional validation. This study aims to explore the safety and efficiency of TA-ESD for early gastric neoplasms located at varying sites, in comparison with conventional endoscopic submucosal dissection (C-ESD).
View Article and Find Full Text PDF